Glenmark ties up with BeiGene for marketing and distribution of Tislelizumab and Zanubrutinib in India
Glenmark will register and commercialise BeiGene’s oncology medicines, Tislelizumab and Zanubrutinib in India
Glenmark Specialty, a subsidiary of Glenmark Pharmaceuticals, a research-led, global pharmaceutical company, today announced an exclusive marketing and distribution agreement with BeiGene, a global oncology company. Under this agreement, Glenmark will register and commercialise BeiGene’s oncology medicines, Tislelizumab and Zanubrutinib in India.
Alok Malik, President and Business Head - India Formulations, Glenmark Pharmaceuticals said, “We are excited about our partnership with BeiGene, signifying our commitment to advancing healthcare in India. The addition of Tislelizumab and Zanubrutinib to our oncology portfolio underscores our dedication to the cancer patients’ community and our commitment to provide access to novel therapies across India.”
“This collaboration is a testament to our shared vision of enhancing healthcare access across Asia," said Adam Roach, Vice President, and Head of Asia-Pacific at BeiGene. “We take great pride in advancing mission-driven access, especially given the significant disease burden in India, where rising cancer rates require comprehensive healthcare solutions - a commitment we share with our partners at Glenmark,” Roach said.
Recommended
Herbalife India, IIT Madras launch 1,000 data science scholarships
November 4, 2024
KIMSHEALTH Nagercoil launches modular OT complex
November 4, 2024
Bayer introduces Bepanthen in India to tackle dry skin
November 4, 2024